Cryoport Inc

CYRX remains in a Stage 2 advancing uptrend with medium-term bullish structure underpinned by sequential higher highs and higher lows, but price is currently extended above the 9 and 21 EMAs without a meaningful pullback. Short-term execution lacks clear edge, so we will defer entry and stalk for a shallow dip into the rising 9/21 and 50 EMA support zone to confirm acceptance before engaging.

• ↑Q1’26 revenue $47.8M (+16% YoY), cell and gene therapy sales $9.1M (+26%)
• ↑Raised FY2026 revenue guidance to $192–196M
• ↓Negative 0.79 earnings yield flags profitability challenges